ReviewJournal of translational medicine2026
Integrin α2: mode of regulation and functioning in the metastatic cancer cascade.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- High-Density Type I Collagen Promotes IFN-γAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundIntegrin α2β1, a major collagen-binding receptor, functions as a key mediator of cell-extracellular matrix (ECM) communication, mechanosensing, and adhesion-dependent signaling. As a core molecular switch in cancer biology, integrin α2 profoundly influences the metastatic cascade-from local invasion, intravasation, survival in circulation, and pre-metastatic niche formation to dormancy and colonization. Although extensive studies indicate that integrin α2β1 regulates tumor proliferation, migration, ECM remodeling, angiogenesis, and immune modulation, its mechanochemical activation mechanisms and context-dependent functions across different stages of metastasis remain incompletely defined. MAIN BODY: This review systematically summarizes the structural characteristics, activation mechanisms, regulatory networks, and functional roles of integrin α2β1 in the cancer metastatic cascade. We first describe the domain architecture of integrin α2, emphasizing the structural determinants underlying ligand specificity and metal ion-dependent adhesion. We then outline multi-level regulatory mechanisms that drive variable integrin α2 expression across tumor types. The dual biochemical and mechanical modes of integrin α2β1 activation are discussed, with emphasis on nanocluster formation, focal adhesion maturation, force-dependent conformational changes, and key downstream signaling pathways. We further dissect the stage-specific contributions of integrin α2β1 at each stage of metastasis, including its contributions to epithelial-mesenchymal transition, matrix metalloproteinase - mediated ECM degradation, vascular remodeling, circulating tumor cell survival, immune evasion, pre-metastatic niche formation, tumor dormancy, and organotropic colonization. Finally, we review current progress in integrin α2-targeted therapies-including small-molecule inhibitors, monoclonal antibodies, natural compounds, and nanomedicine-based delivery systems-and discuss future directions that leverage mechanobiology, integrin-targeted biomaterials, and computational drug design.
conclusionsIntegrin α2β1 is a central mechanochemical regulator of the metastatic cascade, coordinating tumor cell responses to extracellular and intracellular cues. Its functions span critical metastatic processes, making integrin α2 and its downstream pathways promising therapeutic targets. Continued advances in mechanobiology and multi-omics technologies will be essential to refine integrin-centered strategies and improve interventions against metastatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.